Roivant Sciences Ltd. (ROIV)
NEUTRALファンダメンタル
34
株価
$36.47
時価総額
$26.29B
パート1 · 企業の価値
概要
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
貸借対照表と流動性
売上高
$8M
直近12か月（2026/6/30まで）
純利益
$-266M
直近12か月（2026/6/30まで）
フリーキャッシュフロー
$-759M
自己資本合計
$4.53B
負債合計
$416M
流動比率
16.72
利払い倍率
-
負債/EBITDA
-
一株当たり利益（EPS）
売上高と純利益
フリーキャッシュフロー
収益内訳
財務推移表
利益率の推移
負債の推移
負債の重さ
成長率グリッド
成長率 — 売上高
適正価値の推定
適正価値
$41.82
現在株価
$36.47
安全マージン
+12.8%
適正価値レンジ
$39.73 - $43.91
推定方法
バリュエーション指標
P/E レシオ
-
ROE
-6.6%
P/B レシオ
6.21
P/FCF
-
粗利益率
-
ROIC
-9.4%
収益性レーダー
Value Creation (Economic Moat)
ROIC
-9.4%
WACC
10.5%
ROIC − WACC
-19.9 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
ファンダメンタル分析基準
合格（7）
- EPS shows upward trend
- Price CAGR 23.63%
- Debt/Equity ratio
- Current Ratio
- Low reliance on intangibles
- Analyst Consensus 89% Buy
- Share Dilution -22.5%
不合格（11）
- ROIC -9.4%
- P/B Ratio 6.21
- Operating Margin -7914.8%
- Positive Free Cash Flow
- Return on Tangible Assets
- DCF valuation (Unknown)
- ROE -6.1%
- Revenue Growth 5Y -19.1%
- Earnings Surprise avg -2.3%
- Net Margin Trend -3535.0% vs -2111.8%
- Piotroski F-Score 1/9
データなし（9）
- Gross Margin NaN%
- P/FCF NaN
- Dividend Payout NaN%
- CapEx intensity
- Interest Coverage
- Debt/EBITDA
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-スコア
重大な財務上の懸念
利益の質
低品質：会計処理を調査してください
株式希薄化
株式を買い戻している。株主に友好的
ガバナンス
経営陣
| 氏名 | 役職 | 年齢 |
|---|---|---|
| Mr. Matthew Gline | CEO & Director | 41 |
| Dr. Eric Venker M.D., Pharm.D. | President & CEO of Immunovant | 38 |
| Dr. Mayukh Sukhatme M.D. | President, Chief Investment Officer & Director | 49 |
| Dr. Frank M. Torti M.B.A., M.D. | President & Vant Chair | 46 |
| Mr. Richard Pulik | Chief Financial Officer | 45 |
| Ms. Jennifer Humes | Chief Accounting Officer | 44 |
| Mr. Ian Rosenblum | Chief Information Officer | - |
| Mr. Sam Kaplan | General Counsel | - |
| Ms. Kelly Graff | Head of People | - |
| Mr. Alex Gasner | Executive Vice President of Roivant Health | - |
監査リスク
5
取締役会リスク
7
報酬リスク
10
株主権利リスク
4
パート2 · 株価と買い時
この部分は企業に価値があるかを判断するものではありません。ファンダメンタルズに納得したうえで、いつ買うかを選ぶためのものです。内容：テクニカル分析、ポテンシャル、過去のドローダウン、ガンマエクスポージャー。
Latest News
Recent headlines for ROIV, sourced from Markets Gazette.
- 19d agoPOSITIVERoivant Expects FDA to Approve First Major Drug
Roivant Sciences Ltd. is anticipating FDA approval for its novel drug targeting a severe skin condition, with a market launch projected for September. CEO Matt Gline expressed optimism about the drug's potential. This development represents a significant milestone for Roivant, potentially unlocking a new revenue stream and validating its research and development pipeline. Investors will be closely watching the official FDA decision, as approval could lead to substantial growth and market share gains in the dermatology sector.
via Markets Gazette